Please assess the completion status of the following clinical trial:

Trial Title: A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, aged 18 or older (except in South Korea, aged 19 or older).~* Histologically confirmed marginal zone lymphoma, including extranodal, nodal, and splenic subtypes.~* Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥ 1 lesion that measures \> 1.5 cm in the longest transverse diameter and ≥ 1.0 cm in the longest perpendicular diameter.~* Participants with splenic MZL who do not meet the radiographically measurable disease criteria described herein are eligible for participation provided that bone marrow infiltration of MZL is histologically confirmed.~* Participants must be willing to undergo an incisional or excisional lymph node or tissue biopsy or provide a lymph node or tissue biopsy from the most recent available archival tissue.~* Eastern Cooperative Oncology Group performance status 0 to 2.~Exclusion Criteria:~* Evidence of diffuse large B-cell transformation.~* History of central nervous system lymphoma (either primary or metastatic) or leptomeningeal disease.~* Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan-PI3K inhibitor.~* Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment.~* Active graft versus host disease.~* Subjects positive for hepatitis B surface antigen or hepatitis B core antibody will be eligible if they are negative for HBV-DNA. Subjects positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1- Closed to Further enrollment (Type: EXPERIMENTAL): Participants who have received prior ibrutinib.
- Cohort 2 (Type: EXPERIMENTAL): Participants who have not received a prior BTK inhibitor.

Based on this trial design, predict the completion outcome and termination type (if applicable).